Zydus receives USFDA approval for initiating Phase I clinical trials of ‘ZYDPLA1’

23 Oct 2013 Evaluate

Zydus Cadila, an innovative global pharmaceutical company, has received an approval for Phase I clinical trial from the USFDA for ZYDPLA1 - a next generation, long-acting DPP-4 Inhibitor. ZYDPLA1 is an orally active, small molecule NCE, discovered and developed by the Zydus Research Centre, the NCE research wing of Zydus.

ZYDPLA1 is a novel compound in the Gliptin class of anti-diabetic agents. It works by blocking the enzyme Dipeptidyl Peptidase-4 (DPP-4), which inactivate the Incretin hormone GLP-1.

Currently, all available DPP-4 inhibitors are dosed once-daily, ZYDPLA1 with a once-a-week dosing regimen, would provide diabetic patients with a more convenient treatment alternative, ZYDPLA1 will offer sustained action, which will result, in an improved efficacy profile.

Zydus Lifesciences Share Price

901.30 -2.70 (-0.30%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×